With the improvement of oncology diagnosis and treatment, the survival time of cancer patients has been significantly prolonged, and the cancer therapy-related cardiovascular toxicity such as radiotherapy, chemotherapy, immunotherapy, and surgery are becoming more and more prominent, and it is in this context that the germ of Cardio-Oncology exploration has come into being. The multidisciplinary Cardio-Oncology team aims to establish a multidisciplinary prevention and control system to assess patients' baseline risk factors, individualized monitoring, and weighing the risk-benefit ratio of cancer therapy. At present, the connotation of the discipline of Cardio-Oncology has been expanded horizontally and deepened vertically in China, and Cardio-Oncology treatment centers have blossomed all over the country. Moreover, international and domestic scholars continue to improve Cardio-Oncology guidelines and consensus through their own practice, and develop artificial intelligence software to help the development of the discipline. It is believed that in the future, with the training of Cardio-Oncologists and the output of high-quality clinical research evidence, cardiovascular safety of cancer patients can be ensured more scientifically and effectively.
随着肿瘤诊疗水平的不断提高，恶性肿瘤患者生存期显著延长，放疗、化疗、免疫治疗、手术等肿瘤治疗相关心血管毒性问题日益凸显，肿瘤心脏病学探索的萌芽正是在此背景下应运而生。通过在肿瘤治疗前评估患者基线危险因素、个体化监测、权衡肿瘤治疗风险获益，肿瘤心脏病学团队以期建立多学科防控体系。目前国内肿瘤心脏病学学科内涵横向拓展、纵向深化，肿瘤心脏病诊疗中心遍地开花，且国际国内学者们通过自身实践不断完善肿瘤心脏病学领域指南与共识，研发人工智能软件助力学科发展。相信未来随着肿瘤心脏病专科医师的培养、高质量临床研究证据的产出，可更科学有效地保障肿瘤患者心血管安全。.